ReviewMicroorganisms2019
Chloramphenicol Resurrected: A Journey from Antibiotic Resistance in Eye Infections to Biofilm and Ocular Microbiota.
Review in Microorganisms, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 75 citations in OpenAlex.
- Phenotypic characterization, molecular typing, and clonal relatedness within Staphylococcus isolates in healthy ocular conditions.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Chloramphenicol Application Onto the Eyelid: Transfersomes for Enhanced Skin Delivery.AAPS PharmSciTech · 2026Article
- A Dual Quantum Dot Fluorescent Probe for Time-Resolved Chemometric Detection of Chloramphenicolin Pharmaceuticals.Nanomaterials (Basel, Switzerland) · 2026Article
- Global trends of antimicrobial resistance and virulence of Klebsiella pneumoniae from different host sources.Communications medicine · 2025Article
- Emerging Trends in Antimicrobial Resistance in Polar Aquatic Ecosystems.Antibiotics (Basel, Switzerland) · 2025Review
- Characterization of Conjunctival Microflora and Antibiotic Sensitivity Patterns in Patients Undergoing Cataract Surgery.Microorganisms · 2025Article
- Commercially available antiseptics show highFrontiers in veterinary science · 2025Article
- Application of artificial neural network for the mechano-bactericidal effect of bioinspired nanopatterned surfaces.European biophysics journal : EBJ · 2024Article
- Mpox Virus and its ocular surface manifestations.The ocular surface · 2024Review
- Ocular microbiota types and longitudinal microbiota alterations in patients with chronic dacryocystitis with and without antibiotic pretreatment.iMetaOmics · 2024Article
- Development of a luciferase-based Gram-positive bacterial reporter system for the characterization of antimicrobial agents.Applied and environmental microbiology · 2024Article
- In vivo and in vitro efficacy of the ithmid kohl/zinc-oxide nanoparticles, ithmid kohl/Aloe vera, and zinc-oxide nanoparticles/Aloe vera for the treatment of bacterial endophthalmitis.Scientific reports · 2024Article
- Extensively drug-resistant Salmonella typhi Infection in Adults; Experience from A Tertiary Care Hospital.Pakistan journal of medical sciences · 2024Article
- Antibiotic use and resistance patterns at Rumphi District Hospital in Malawi: a cross-sectional study.BMC infectious diseases · 2024Article
- Anti-Staphylococcal Biofilm Effects of a Liposome-Based Formulation Containing Citrus Polyphenols.Antibiotics (Basel, Switzerland) · 2024Article
- Nanomaterials Based on 2,7,12,17-Tetra-tert-butyl-5,10,15,20-tetraaza-21H,23H-porphine Exhibiting Bifunctional Sensitivity for Monitoring Chloramphenicol and CoBiomedicines · 2024Article
- Article
- Comparison Between Moxifloxacin and Chloramphenicol for the Treatment of Bacterial Eye Infections.Current therapeutic research, clinical and experimental · 2024Article
- Susceptibility of Ocular Surface Bacteria to Various Antibiotic Agents in a Romanian Ophthalmology Clinic.Diagnostics (Basel, Switzerland) · 2023Article
- N-Acetylcysteine and Its Immunomodulatory Properties in Humans and Domesticated Animals.Antioxidants (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent of multidrug resistance among pathogenic bacteria is devastating the worth of antibiotics and changing the way of their administration, as well as the approach to use new or old drugs. The crisis of antimicrobial resistance is also due to the unavailability of newer drugs, attributable to exigent regulatory requirements and reduced financial inducements. The emerging resistance to antibiotics worldwide has led to renewed interest in old drugs that have fallen into disuse because of toxic side effects. Thus, comprehensive efforts are needed to minimize the pace of resistance by studying emergent microorganisms and optimize the use of old antimicrobial agents able to maintain their profile of susceptibility. Chloramphenicol is experiencing its renaissance because it is widely used in the treatment and prevention of superficial eye infections due to its broad spectrum of activity and other useful antimicrobial peculiarities, such as the antibiofilm properties. Concerns have been raised in the past for the risk of aplastic anemia when chloramphenicol is given intravenously. Chloramphenicol seems suitable to be used as topical eye formulation for the limited rate of resistance compared to fluoroquinolones, for its scarce induction of bacterial resistance and antibiofilm activity, and for the hypothetical low impact on ocular microbiota disturbance. Further in-vitro and in vivo studies on pharmacodynamics properties of ocular formulation of chloramphenicol, as well as its real impact against biofilm and the ocular microbiota, need to be better addressed in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.